US · ZVRA
Zevra Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Celebration, FL 34747
- Website
- zevra.com
Price · as of 2024-12-31
$10.07
Market cap 502.74M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $19.63 | +94.94% |
| Intrinsic Value(DCF) | $1,097.03 | +10,794.04% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $12.00 | +19.18% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $224.80 | ||||
| 2016 | $63.20 | ||||
| 2017 | $108.80 | ||||
| 2018 | $31.04 | ||||
| 2019 | $4.48 | ||||
| 2020 | $9.39 | $363.36 | $0.00 | $0.00 | $0.00 |
| 2021 | $5.23 | $360.01 | $3.75 | $2.83 | $0.00 |
| 2022 | $4.13 | $114.17 | $0.76 | $0.00 | $41.65 |
| 2023 | $6.10 | $41.90 | $9,116.83 | $0.00 | $0.00 |
| 2024 | $8.10 | $19.63 | $0.00 | $0.00 | $12.00 |
AI valuation
Our deep-learning model estimates Zevra Therapeutics, Inc.'s (ZVRA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $19.63
- Current price
- $10.07
- AI upside
- +94.94%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1,097.03
+10,794.04% upside
Graham-Dodd
—
— upside
Graham Formula
$12.00
+19.18% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ZVRA | Zevra Therapeutics, Inc. | $10.07 | 502.74M | +95% | +10,794% | — | +19% | -3.55 | 9.44 | 15.87 | -4.78 | -4.71 | -11.01 | 68.59% | -368.47% | -446.85% | -207.84% | -254.55% | -60.21% | 1.52 | -11.84 | 2.53 | 2.35 | -0.35 | 7538.00% | -1402.00% | 10592.00% | -18.60% | -2.05 | -203.82% | 0.00% | 0.00% | 0.00% | -4.20 | -5.25 | 15.48 | -3.48 |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | 347.63M | +2,616% | +600% | — | — | -60.62 | 9.94 | 1.37 | -56.76 | — | -12.26 | 83.29% | 9.95% | -2.26% | 64.49% | -72.80% | -1.79% | 0.00 | 0.97 | 1.13 | 1.42 | 75.38 | -9370.00% | 4746.00% | -26637.00% | 20.89% | 0.42 | -209.73% | 0.00% | 0.00% | 99.29% | 5.92 | 2.06 | 0.59 | -4.79 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| GOSS | Gossamer Bio, Inc. | $0.42 | 98.35M | — | +201% | — | — | -4.84 | 9.28 | 2.39 | -4.56 | — | 9.28 | 100.00% | -52.24% | -49.28% | -122.54% | 143.80% | -18.03% | 6.88 | -5.20 | 6.88 | 6.66 | -3.92 | -7881.00% | — | -9782.00% | -1.27% | -0.08 | 8.32% | 0.00% | 0.00% | 8.83% | -3.04 | -52.51 | 1.59 | -4.31 |
| KALV | KalVista Pharmaceuticals,… | $16.28 | 822.89M | — | — | — | — | -3.93 | 7.56 | — | -3.11 | -54.08 | 7.56 | 0.00% | — | — | -121.50% | 456.02% | -75.46% | 0.07 | -32.50 | 5.35 | 4.49 | 0.53 | 727.00% | — | 7100.00% | -21.27% | -3.39 | 371.96% | 0.00% | 0.00% | 9.41% | -2.87 | -3.52 | — | -2.40 |
| NAGE | Niagen Bioscience Inc | $5.05 | 403.02M | +585% | +258% | -79% | -47% | 76.93 | 14.27 | 6.60 | 66.87 | — | 14.38 | 61.84% | 7.76% | 8.58% | 22.94% | 169.60% | 13.88% | 0.06 | — | 3.57 | 2.91 | -4.54 | -26692.00% | 1918.00% | 7142.00% | 1.82% | 0.67 | 271.59% | 0.00% | 0.00% | 2.73% | 79.72 | 51.56 | 6.18 | 16.70 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| PRTA | Prothena Corporation plc | $8.67 | 466.71M | +225% | -47% | — | +4,117% | -2.07 | 1.80 | 52.25 | -1.06 | -2.08 | 1.80 | 0.00% | -1905.82% | -2520.57% | -63.62% | -2799.76% | -55.86% | 0.05 | — | 7.72 | 7.53 | 1.46 | 9956.00% | -9283.00% | 889.00% | -32.36% | -4.01 | -2483.59% | 0.00% | 0.00% | 0.00% | -1.15 | -1.30 | 21.92 | 5.73 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
- CEO
- Neil F. McFarlane
- Employees
- 59
- Beta
- 0.92
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1,097.03 ÷ $10.07) − 1 = +10,794.04% (DCF, example).